In spite of Covid-19 and global recession concerns, we have a positive outlook on the biotechnology sub-industry; we expect to see a ramp-up in new drug sales; the continued development of many new, innovative therapies; and a decline in the prevalence of patent expirations in 2020 and 2021.
CFRA Analysts Highlight 6 Health Sector Buys For Your Portfolio
